Presentation is loading. Please wait.

Presentation is loading. Please wait.

Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products? 

Similar presentations


Presentation on theme: "Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products? "— Presentation transcript:

1 Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products? 

2

3 Introduction/Overview

4 Prophylaxis is the Recommended Therapeutic Regimen

5 Key Unmet Needs in Hemophilia B

6 Potential Barriers to Adherence in Hemophilia B Prophylaxis

7 Extended Half-Life Agents and Treatment Individualization

8 The Importance of Maintaining Trough Levels to Prevent Breakthrough Bleeding

9 Pharmacokinetics of 3 Extended Half-Life Agents

10 Improving Adherence in Hemophilia B

11 Higher Factor Activity Levels Can Reduce Average Number of Joint Bleeds

12 Any Joint Bleeding May Be Too Much Joint Bleeding

13 rFIX Molecules With Extended Half-Lives

14 rFIX-FP

15 PROLONG: FIX Activity After Injection of a Single Dose of rFIX-FP or Previous FIX Product (PK Population)

16 PROLONG: AsBR: Prophylaxis Patients

17 PROLONG: Safety Results

18 rFIX-Fc

19 B-LONG: rFIX-Fc Fusion Protein: PK Results

20 B-LONG: Median ABR

21 B-LONG: Safety Results

22 Kids B-LONG: Study Results

23 Glycol PEGylated rFIX

24 PARADIGM 2 N9-GP: Annualized Bleeding Rates Results

25 PARADIGM 2 N9-GP: Mean Predose FIX Activity

26 PARADIGM 5 N9-GP: Overview of Results

27 Prolonged Exposure to PEGylation in PWH-B: Cause For Concern?

28 Relevance of Differences Among the 3 Extended Half-Life rFIX Agents

29 Switching Patient From Standard to Extended Half-Life rFIX Agents

30 Summary and Conclusions

31 Abbreviations

32 Abbreviations (cont)


Download ppt "Would Patients With Hemophilia B Benefit From Switching to Extended Half-Life Factor Products? "

Similar presentations


Ads by Google